Provided by Tiger Fintech (Singapore) Pte. Ltd.

FibroGen

0.3334
-0.0053-1.56%
Post-market: 0.33340.00000.00%16:00 EDT
Volume:269.41K
Turnover:90.84K
Market Cap:33.65M
PE:-0.70
High:0.3430
Open:0.3400
Low:0.3331
Close:0.3387
Loading ...

Company Profile

Company Name:
FibroGen
Exchange:
NASDAQ
Establishment Date:
1993
Employees:
225
Office Location:
350 Bay Street,Suite 10 #6009,San Francisco,California,United States
Zip Code:
94133
Fax:
415 978 1902
Introduction:
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Directors

Name
Position
Thomas B. Neff
Chairman, Founder, Chief Executive Officer, and Director
James A. Schoeneck
Director
Jeffrey L. Edwards
Director
Jeffrey W. Henderson
Director
Jorma Routti
Director
Julian N. Stern
Director
Kalevi Kurkijarvi
Director
Roberto Pedro Rosenkranz
Director
Rory B. Riggs
Director
Thomas F. Kearns
Director
Toshinari Tamura
Director

Shareholders

Name
Position
Thomas B. Neff
Chairman, Founder, Chief Executive Officer, and Director
Pat Cotroneo
Vice President, Finance, and Chief Financial Officer
K. Peony Yu
Chief Medical Officer